To our employees, partners and valued customers
As a privately-owned family business, we do not report financials to the market, but we do feel it’s important to provide regular business updates to our customers and business partners. As such, we have done this at regular 6-month intervals since 2017.
As the first half of 2020 draws to a close, I wanted to provide you with the latest business update for the Agarose Chromatography division of Purolite Life Sciences.
INNOVATION COMMITMENT AND GROWTH PLAN
We first started our Praesto® bioprocessing resin journey back in 2014, and commercialised our first ion exchange chromatography resin shortly after, in 2015. By 2016, Praesto® was successfully implemented into human clinical trials, and our first alkaline-tolerant protein A resin was launched. Response from the market was overwhelmingly positive, allowing us to continue to invest heavily into protein A resin improvements and innovation.
To set the scene for the market conditions during that time, the vast majority of the biopharmaceutical developers were using a well-established but dated resin technology for their mAb processes. This traditional ‘batch emulsified’ resin technology was first developed in the 1950s as a method of producing agarose base beads. With only minor modifications being implemented over the ensuing 60 years, fundamentally, the technology provided the same limitations in 2015 as it did when it was first developed. It’s interesting to compare this scenario to the automotive industry, where in that same time period we have continually seen major advancements to improve safety, reliability and environmental impact through electric vehicles, as market attitudes have shifted over time. Whilst significant advancements have been made in the biopharmaceutical industry in that timeframe - where there is a strong focus on improved productivity and cost of goods to promote better access to affordable therapeutics – it was interesting to note that in 2015 production of these novel, vital treatments were still relying on a 60 year old technology. Jumping forward to 2020, it’s a fair and unfortunately sobering statement that the current Covid-19 pandemic that we continue to face together has only heightened the need for rapid, cost-effective and reliable production of biopharmaceuticals.
OUR VISION - BRILLIANCE IN BASE BEADS
As a global leader in resin bead production since 1981, and the only global company to focus solely on resin technology, Purolite® knew that only we could break the status quo, re-write the rule book, and truly re-invent the agarose base bead to be suitable for modern and future processing demands. We knew that Praesto® products would have to perform better, our lead times would have to be shorter, and our technical staff would have to be the best in their fields to truly make an impact. With that ethos, our vision became clear and we developed the patented, and now industry-standard technology, referred to as Jetting.
BEST-IN-CLASS MANUFACTURING - JETTING TECHNOLOGY
Jetting truly innovated agarose base bead production, allowing us to precisely control bead size and distribution to deliver higher consistency, enhanced performance, shorter lead times, and significantly reduced environmental footprint. The process uses no solvents, and provides 100% yield (this can be as low as 60% in batch emulsification production) and produces uniform beads of a target size, with no fine particles. This eliminates the need for a time-consuming and costly sieving step during manufacture. The lack of fine particles in Praesto® Jetted resins offers several benefits, such as:
These benefits, combined with fair pricing and an industry-leading commitment to security of supply have allowed our Jetting technology to support the biopharmaceutical industry in improving both the affordability and availability of life-saving treatments all across the globe.
- Faster processing through higher flow velocities
- More reliable and reproducible column packing
- Increased resin lifetime
- No column net clogging